



February 14, 2020
Gene Techno Science Co., Ltd.
Code: 4584 (TSE Mothers)
Masaharu Tani, President & CEO

Announcement of Business Alliance Agreement with DOJIN GROUP Co, Ltd. for business development in regenerative medicine and healthcare area

Tokyo, February 14, 2020 – Gene Techno Science Co., Ltd. (“GTS”) signed a business alliance agreement with DOJIN GROUP Co., Ltd (“DOJIN”) for business development in regenerative medicine and healthcare area.

1. Purpose of this agreement

DOJIN promotes businesses in the sales of pharmaceuticals, medical devices, research reagents, and also culture and storage of cells using regenerative medicine technology with the broad network in Japan and overseas. GTS is actively engaged in research and development activities for the clinical applications in collaboration with research institutes and partner companies by the use of stem cells from exfoliated deciduous teeth (“SHED”) collected from associated dental clinics.

Both companies agreed that the development of a new business combining the business base of DOJIN and our SHED platform would enhance the enterprise value, and then, made this agreement by concluding that it is best to establish more solid partnership. Specifically, we will examine the business development for clinical application of SHED utilizing resources and distribution networks in a wide range of fields such as pharmaceuticals, medical equipment, reagents, etc., which the DOJIN has established till today. GTS will continue to discuss to strengthen our cooperation, work to further expand our business, and advance our new biotech business to accelerate the enhancement of our enterprise value, with the aim of realizing GTS 3.0 as soon as possible.

2. Outline of counterparties to this agreement

1. Name	DOJIN Group Co., Ltd.
2. Location	1-44-2 Ryutsudanchi, Minami-ku, Kumamoto
3. CEO	Keima Ueno

4. Main Business	Sale of pharmaceuticals, medical devices, research reagents
5. Capital	21 thousand Japanese Yen
6. Established	April 26, 2019

3. Future outlook

The impact on the business results for the fiscal year ending March 2020 is expected to be minimal.

About Gene Techno Science Co., Ltd.

GTS announced GTS 3.0 “Biotech Engineering Company, striving for value creation” a new business stage starting from this fiscal year, which targeted the pediatric disease in addition to the areas GTS has been engaged in such as the orphan disease and intractable disease. By leveraging the knowhow and expertise about biotechnology acquired in the past business activities, GTS is working on the development and provision of new medicines and therapeutic treatment for the purpose of achieving comprehensive healthcare solutions for the patients suffering from these diseases as well as families and caregivers.

Contact:

Gene Techno Science Co., Ltd.

Tel: +81-3-6222-9547 Mail: info@g-gts.com